Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroblastoma × Pharmaceutical Preparations × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 9 Neoplasms 4 Melanoma 4 Breast Neoplasms 4 Lymphoma, B-Cell, Marginal Zone 3 Lymphoma 3 Sarcoma 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Polycystic Ovary Syndrome 2 Pleural Effusion, Malignant 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Head and Neck Neoplasms 2 Anxiety Disorders 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Recurrence 1 Rare Malignant Neoplasm 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Neoplasms, Plasma Cell 1 NSCLC 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphedema 1 Locally Advanced Bladder Cancer 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 53 Etoposide 33 Temozolomide 28 Irinotecan 28 Melphalan 25 Filgrastim 25 Topotecan 24 Carboplatin 24 3-Iodobenzylguanidine 23 Isotretinoin 20 Granulocyte Colony-Stimulating Factor 17 sargramostim 16 humanized 3F8 anti-GD2 monoclonal antibody 16 dinutuximab 16 Granulocyte-Macrophage Colony-Stimulating Factor 16 fludarabine 15 Vincristine 15 Doxorubicin 15 Cisplatin 15 Peripheral Blood Stem Cell Transplantation 14 Interleukin-2 14 Busulfan 13 naxitamab 12 Thiotepa 12 Radiotherapy 12 aldesleukin 11 fludarabine phosphate 10 etoposide phosphate 8 Mesna 8 Ifosfamide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07334301 2026-01-12

BEACON2

University of Birmingham

Phase 1/2 Recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡